Taylor F Smith1, Jessica A Kaczorowski1, Maria T Acosta2,3. 1. Department of Psychology and Child Development, California Polytechnic State University, San Luis Obispo, San Luis Obispo, CA, USA. 2. Office of the Clinical Director and Medical Genetic Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. acostam@mail.nih.gov. 3. National Human Genome Research Institute, National Institutes of Health, Building 10, Room 3 I485 NE, Bethesda, MD, 20892-3717, USA. acostam@mail.nih.gov.
Abstract
PURPOSE: Neurofibromatosis type 1 (NF1) is a rare monogenic disorder associated with executive function (EF) deficits and heightened risk for attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The goal of this paper is to understand how EFs provide a common foundation to understand vulnerabilities for ADHD and ASD within NF1. METHODS: A literature review and synthesis was conducted. RESULTS: EF difficulties in working memory, inhibitory control, cognitive flexibility, and planning are evident in NF1, ADHD, and ASD. However, relatively little is known about the heterogeneity of EFs and ADHD and ASD outcomes in NF1. Assessment of ADHD and ASD in NF1 is based on behavioral symptoms without understanding neurobiological contributions. Recent efforts are promoting the use of dimensional and multidisciplinary methods to better understand normal and abnormal behavior, including integrating information from genetics to self-report measures. CONCLUSION: NF1 is a monogenic disease with well-developed molecular and phenotypic research as well as complementary animal models. NF1 presents an excellent opportunity to advance our understanding of the neurobiological impact of known pathogenic variation in normal and abnormal neural pathways implicated in human psychopathology. EFs are core features of NF1, ADHD, and ASD, and these neurodevelopmental outcomes are highly prevalent in NF1. We propose a multilevel approach for understanding EFs in patients with NF1.This is essential to advance targeted interventions for NF1 patients and to advance the exciting field of research in this condition.
PURPOSE: Neurofibromatosis type 1 (NF1) is a rare monogenic disorder associated with executive function (EF) deficits and heightened risk for attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The goal of this paper is to understand how EFs provide a common foundation to understand vulnerabilities for ADHD and ASD within NF1. METHODS: A literature review and synthesis was conducted. RESULTS: EF difficulties in working memory, inhibitory control, cognitive flexibility, and planning are evident in NF1, ADHD, and ASD. However, relatively little is known about the heterogeneity of EFs and ADHD and ASD outcomes in NF1. Assessment of ADHD and ASD in NF1 is based on behavioral symptoms without understanding neurobiological contributions. Recent efforts are promoting the use of dimensional and multidisciplinary methods to better understand normal and abnormal behavior, including integrating information from genetics to self-report measures. CONCLUSION: NF1 is a monogenic disease with well-developed molecular and phenotypic research as well as complementary animal models. NF1 presents an excellent opportunity to advance our understanding of the neurobiological impact of known pathogenic variation in normal and abnormal neural pathways implicated in human psychopathology. EFs are core features of NF1, ADHD, and ASD, and these neurodevelopmental outcomes are highly prevalent in NF1. We propose a multilevel approach for understanding EFs in patients with NF1.This is essential to advance targeted interventions for NF1 patients and to advance the exciting field of research in this condition.
Authors: Maria T Acosta; Carrie E Bearden; F Xavier Castellanos; Xavier F Castellanos; Laurie Cutting; Ype Elgersma; Gerard Gioia; David H Gutmann; Yong-Seok Lee; Eric Legius; Maximillian Muenke; Kathryn North; Luis F Parada; Nancy Ratner; Kim Hunter-Schaedle; Alcino J Silva Journal: Am J Med Genet A Date: 2012-07-20 Impact factor: 2.802
Authors: Karin S Walsh; Jorge I Vélez; Peter G Kardel; Daniel M Imas; Maximilian Muenke; Roger J Packer; Francisco X Castellanos; Maria T Acosta Journal: Dev Med Child Neurol Date: 2012-11-16 Impact factor: 5.449
Authors: David H Gutmann; Rosalie E Ferner; Robert H Listernick; Bruce R Korf; Pamela L Wolters; Kimberly J Johnson Journal: Nat Rev Dis Primers Date: 2017-02-23 Impact factor: 52.329
Authors: Johanna Uthoff; Jared Larson; Takashi S Sato; Emily Hammond; Kimberly E Schroeder; Frank Rohret; Christopher S Rogers; Dawn E Quelle; Benjamin W Darbro; Rajesh Khanna; Jill M Weimer; David K Meyerholz; Jessica C Sieren Journal: Sci Rep Date: 2020-03-19 Impact factor: 4.996
Authors: Eve Lalancette; Audrey-Rose Charlebois-Poirier; Kristian Agbogba; Inga Sophia Knoth; Emily J H Jones; Luke Mason; Sébastien Perreault; Sarah Lippé Journal: J Neurodev Disord Date: 2022-07-22 Impact factor: 4.074